Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 9 Hyperandrogenism 4 Neoplasms 3 Skin Diseases 1 Sarcoma 1 Rare Diseases 1 Obesity 1 Metabolic Syndrome 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Inflammation 1 Hematologic Neoplasms 1 Heart Failure 1 Glioblastoma 1 Endocrine System Diseases 1 Critical Illness 1 Cardiovascular Diseases 1 Cardiotoxicity 1 Breast Neoplasms 1 Advanced Malignant Neoplasm 1 Acute Kidney Injury 1 Acanthosis Nigricans 1

Interventions

Exercise 5 Vitamin D 3 Resistance Training 3 Omeprazole 3 Etanercept 3 Dexmedetomidine 3 Ascorbic Acid 3 salicylsalicylic acid 2 palbociclib 2 epigallocatechin gallate 2 XENP 1595 2 Tea 2 Tablets 2 Sufentanil 2 Probiotics 2 Nutrition Assessment 2 Morphine 2 Metformin 2 Ketorolac 2 Infliximab 2 Ibuprofen 2 Fish Oils 2 Endurance Training 2 Colchicine 2 Aspirin 2 soybean oil, phospholipid emulsion 1 montelukast 1 microcrystalline cellulose 1 ginger extract 1 falcarinol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Inflammation × Spironolactone × Clear all

NCT02689843 2019-11-12

AntiPCO

Shiraz University of Medical Sciences

Phase EARLY_PHASE1 Completed

Inflammation, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡